Magnetic therapy to treat chronic migraine developed

Washington, Apr 30 (ANI): A new therapy that uses magnetic pulses has shown promise in treating chronic migraine sufferers, say researchers.

The new therapy is called transcranial magnetic stimulation, or TMS.

During the study conducted in rats, the University of California, San Francisco researchers focused on understanding the mechanism of action of TMS therapy — how the treatment interacted with the brain to produce the pain-free outcomes of patients.

They identified potential opportunities to enhance treatment strategies in patients.

The study team noted that factors such as time and peak intensity of stimulation may be important components in the brain’s response to TMS.

“The data demonstrate a biological rationale for the use of TMS to treat migraine aura,” said Peter Goadsby, lead investigator of the study, professor and director of the UCSF Headache Centre.

“We found that cortical spreading depression, known as CSD and the animal correlate of migraine aura, was susceptible to TMS therapy, with the wave of neuronal excitation blocked on over 50 percent of occasions,” he added.

The study showed that migraine aura, a condition in which a variety of mostly visual sensations come before or accompany the pain of a migraine attack, responds to magnetic stimulation.

The magnetic pulses block the wave of neuronal excitation, which is a biological system through which neurons become stimulated to fire.

TMS creates a focused magnetic pulse that passes noninvasively through the skull, inducing an electric current to disrupt the abnormal brain waves believed to be associated with migraine, including CSD. CSD in humans precedes migraine with aura.

The researchers hope that the findings give neurologists a potential new treatment option for migraine sufferers unable to tolerate medication.

The findings were presented during the annual American Academy of Neurology scientific meeting in Seattle. (ANI)

Ultrasound-tPA combo more effective for stroke

Washington, February 20 (ANI): Scientists presenting a study at the American Stroke Association’s International Stroke Conference in San Diego revealed that an experimental therapy using tiny bubbles activated by transcranial Doppler (TCD) ultrasound, combined with the clot busting drug tissue plasminogen activator (tPA), might prove more effective than tPA alone in treating patients suffering from ischemic stroke.

Dr. Andrei Alexandrov, director of the University of Alabama at Birmingham (UAB) Comprehensive Stroke Center, and Dr. Carlos Molina, of the Vall d’Hebron Hospital in Barcelona, Spain, have discovered that patients can be treated safely with TCD in combination with a specific dose of the bubbles, called microspheres, and tPA.

The microspheres, developed by ImaRx Therapeutics, are tiny gas-filled lipid structures that cavitate (rapidly expand and collapse) when exposed to ultrasound waves, helping to reopen blocked arteries and restore blood flow.

“These findings demonstrate that ultrasound combined with microspheres and tPA can be tested further in a pivotal clinical trial with the goal of providing a more effective treatment option for stroke patients by promoting faster clearing of blocked blood vessels as well as improved patient outcomes. It’s very promising to see such results, which support the potential of this therapy as a more effective and expansive therapy for stroke patients,” said Alexandrov, UAB professor of neurology.

During two trial phases, two different doses of ImaRx’s MRX-801 microspheres were tested on 35 patients.

Cohort I and cohort II patients received 1.4 mL and 2.8 mL of microspheres respectively, while control patients received the standard dose of tPA alone.

The research team observed that complete recanalization was achieved in 120 minutes in 67 percent of cohort I patients, in 46 percent of cohort II patients, and 33 percent of control patients.

According to them, significant clinical recovery was observed in 45 percent of cohort I, 10 percent of cohort II, and 27 percent of controls.

Besides that, the researchers also saw clinical improvement after 90 days in 75 percent of cohort I, 50 percent of cohort II, and 36 percent of controls. (ANI)